PTG-300

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

β-thalassemia

Conditions

β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia

Trial Timeline

Dec 19, 2018 → Jul 31, 2020

NCT ID

NCT03802201

About PTG-300

PTG-300 is a phase 2 stage product being developed by Protagonist Therapeutics for β-thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03802201. Target conditions include β-thalassemia, Ineffective Erythropoiesis, Chronic Anemia.

What happened to similar drugs?

1 of 2 similar drugs in β-thalassemia were approved

Approved (1) Terminated (1) Active (1)

✅DeferasiroxNovartisApproved

🔄DeferasiroxNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04767802	Phase 2	Completed	Feb 2, 2021	Mar 15, 2023	Polycythemia Vera
NCT04516382	Phase 1	Completed	Sep 14, 2020	Jun 30, 2021	Healthy Volunteers
NCT04202965	Phase 2	Completed	Mar 19, 2020	Feb 15, 2022	Hereditary Hemochromatosis
NCT04054921	Phase 2	Completed	May 10, 2019	Jul 31, 2020	β-thalassemia
NCT03802201	Phase 2	Completed	Dec 19, 2018	Jul 31, 2020	β-thalassemia

Competing Products

8 competing products in β-thalassemia

See all competitors

Product	Company	Stage	Hype Score
luspatercept	Merck	Phase 2	35
Deferasirox	Novartis	Approved	35
Deferasirox + Deferoxamine (DFO)	Novartis	Phase 2	27
Deferasirox	Novartis	Phase 1	29
Deferasirox	Novartis	Phase 3	40
Luspatercept	Bristol Myers Squibb	Pre-clinical	30
Luspatercept	Bristol Myers Squibb	Pre-clinical	33
PTG-300	Protagonist Therapeutics	Phase 2	32